India’s Syngene International Acquires First U.S. Biologics Facility for $36.5 Million!
Bengaluru, India – March 11, 2025: Syngene International, a leading contract research and manufacturing firm based in India, has announced the acquisition of its first Biologics facility in the United States. The company is purchasing the facility from Emergent Manufacturing Operations Baltimore, a unit of Emergent BioSolutions, for $36.5 million. This strategic move strengthens Syngene International’s global footprint and enhances its Biologics manufacturing capabilities.
Strategic Expansion to Reduce Dependence on China
The acquisition aligns with a broader industry trend aimed at diversifying manufacturing operations and reducing dependency on China. By establishing a strong presence in the U.S., Syngene International is aiming to provide high-quality Biologics development and manufacturing solutions to its global clients while capitalizing on the regularly growing demand for biopharmaceutical services in North America.
The newly acquired facility is strategically located near key Biotechnology hubs in the Northeast U.S., which is enabling Syngene International to tap into a rich ecosystem of Pharmaceutical and Biotechnology companies. This proximity will facilitate collaboration with potential partners and clients in the region, reinforcing Syngene’s position as a worldwide leader in contract research, development, as well as manufacturing services.
Operational Timeline & Capacity Expansion
Syngene International has stated that the facility is expected to be fully operational for client projects by the second half of 2025. The acquisition will considerably increase Syngene International’s single-use bioreactor capacity from 20,000 to 50,000 liters. This would enable the company to scale up its large molecule discovery, development, as well as manufacturing services.
Deepak Jain, Chief Financial Officer of Syngene International, shared his thoughts and stated, “The acquisition of this facility represents a significant step in Syngene’s strategy to expand its global Biologics capabilities. In the short term, we expect minor dilution of operating margins due to the costs associated with this facility. However, in the long term, this investment will enhance our service offerings and drive revenue growth.”
He emphasized that acquiring this facility is a critical step toward the growth of the company’s Biologics business worldwide. In the short term, Syngene International could witness a slight drop in profits because of the expenditure involved in setup as well as the running of the facility. Furthermore, in the future, this investment would help the company increase its revenue as well as offer more services to clients globally.
India’s Growing CDMO Market
The acquisition happened when the CDMO (Contract Research Development and Manufacturing Organization) sector in India was witnessing exponential growth!
Boston Consulting Group reported that “India’s CDMO market has the potential to expand seven-fold, reaching $22 billion to $25 billion by 2035.”
Syngene International’s expansion into the United States positions the company favorably to capitalize on this growth. This would strengthen its relationships with the Biopharmaceutical companies seeking scalable as well as reliable Bio-manufacturing partners.
Future Outlook
With an increasing demand for contract manufacturing services as well as an expanding pipeline of Biologics projects, Syngene International is reasonably well-positioned to utilize its growing and evolving capabilities to attract the global market. The company’s strategic investment in the United States is expected to enhance its ability to serve its clients in the Biopharmaceutical sector as well as speed up its growth trajectory.
As Syngene International integrates the new facility into its operations, it’s committed to maintaining regulatory compliance as well as high-quality standards. This would ensure that its Biologics Manufacturing Services continue to provide for the growing needs of the global healthcare sector.
Syngene Acquires
